Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab in Erdheim-Chester Disease
NCT01727206Phase 2Terminated
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Nov 2012
- Primary completion
- Feb 2015
- Countries
- 1
01
Overview
A Phase 2 trial of tocilizumab in Erdheim-Chester disease (ECD), sponsored by IRCCS Ospedale San Raffaele. Started Nov 2012; status: terminated.
02
Drugs
tocilizumab
03
Conditions
Erdheim-Chester disease (ECD)
Beyond the preview
Go deeper on NCT01727206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01727206.